1. Search Result
Search Result
Results for "

GA

" in MedChemExpress (MCE) Product Catalog:

125

Inhibitors & Agonists

3

Fluorescent Dye

16

Biochemical Assay Reagents

29

Peptides

1

Inhibitory Antibodies

8

Natural
Products

11

Recombinant Proteins

2

Isotope-Labeled Compounds

7

Antibodies

8

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147082
    GA-017
    2 Publications Verification

    YAP Cancer
    GA-017 is a potent and selective LATS1 and LATS2 (large tumor suppressor kinase 1/2) inhibitor, with IC50 values of 4.10 and 3.92 nM, respectively. GA-017 is an activator of cell proliferation. GA-017 promotes YAP/TAZ activation and nuclear translocation. GA-017 promotes cell growth under 3D culture conditions. GA-017 enhances the ex vivo formation of mouse intestinal organoids .
    GA-017
  • HY-126558

    Phytohormone Others
    GA3-AM is a cell permeable analog of the plant hormone gibberellic acid that acts as a chemical dimerizer or chemical inducer of dimerization .
    GA3-AM
  • HY-163340

    Glucocorticoid Receptor Androgen Receptor Cancer
    GA32 (compound 58r) is potent androgen receptor (AR)/glucocorticoid receptor (GR) dual inhibitor with IC50 values of 0.13 μM and 0.83 μM for AR and GR, respectively. GA32 inhibits the proliferation of Enzalutamide (HY-70002) resistance castration-resistant prostate cancer both in vitro and in vivo .
    GA32
  • HY-126558R

    Phytohormone Others
    GA3-AM (Standard) is the analytical standard of GA3-AM. This product is intended for research and analytical applications. GA3-AM is a cell permeable analog of the plant hormone gibberellic acid that acts as a chemical dimerizer or chemical inducer of dimerization .
    GA3-AM (Standard)
  • HY-164479

    Histone Methyltransferase Autophagy Apoptosis Cancer
    GA001 is a potent G9a antagonist, with an IC50 of 1.32 μM. GA001 induces autophagy and apoptosis that can be used for the breast cancer .
    GA001
  • HY-167886

    Angiotensin Receptor Cardiovascular Disease
    GA 0113 is a potent and orally active angiotensin II (Ang II) AT1-receptor antagonist. GA 0113 inhibits the Ang II (HY-13948)-induced pressor response with ID50 of 0.032 mg/kg and dose-dependently increases plasma renin activity for 48 h .
    GA 0113
  • HY-145854

    Bacterial Infection Inflammation/Immunology
    GA-O-06, a 18β-Glycyrrhetinic acid derivative, is a potent antimicrobial and anti-inflammatory agent. GA-O-06 exerts anti-inflammation through the inhibition of NO, pro-inflammatory cytokines and chemokines. GA-O-06 displays a high antimicrobial activity against Gram-positive bacteria .
    GA-O-06
  • HY-145853

    Bacterial Infection Inflammation/Immunology
    GA-O-02, a 18β-Glycyrrhetinic acid derivative, is a potent antimicrobial and anti-inflammatory agent. GA-O-02 exerts anti-inflammation through the inhibition of NO, pro-inflammatory cytokines and chemokines. GA-O-02 displays a high antimicrobial activity against Gram-positive bacteria .
    GA-O-02
  • HY-135214

    Aldehyde Dehydrogenase (ALDH) Cancer
    GA11 is an ALDH inhibitor that shows activity against glioblastoma both in vitro and in vivo .
    GA11
  • HY-168343

    Biochemical Assay Reagents Cancer
    Ga-DOTA-Olmutinib is a potential PET tracer designed to detect EGFR-positive cancers .
    Ga-DOTA-Olmutinib
  • HY-D1289

    Fluorescent Dye Others
    GA-PEG5-bromide is a probe used for molecular labeling.
    GA-PEG5-bromide
  • HY-N11643

    GA-Mk

    Apoptosis Reactive Oxygen Species (ROS) MMP Caspase Cancer
    Ganoderic acid Mk (GA-Mk) is a triterpenoid acid, that can be isolated from the mycelia of Ganoderma lucidum. Ganoderic acid Mk is efficiently anti-proliferative and can induce apoptosis of HeLa cells by mitochondria-mediated pathway. Ganoderic acid Mk can be used for cervical cancer research .
    Ganoderic acid Mk
  • HY-P9910

    GA101; Anti-Human CD20 type II, Humanized Antibody

    CD20 Cancer
    Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
    Obinutuzumab
  • HY-125572

    GA7

    Endogenous Metabolite Reactive Oxygen Species (ROS) Fungal Infection
    Gibberellin A7 (GA7) is a terpenoid that serve as an important plant hormone. Gibberellin A7 acts as a growth and response modulator against injuries and parasitism. Gibberellin A7 presents antibiofilm properties at 940 mM concentration. Gibberellin A7 can inhibit flower bud formation in some plants. Gibberellin A7 shows antioxidant activity against peroxyl radicals. Gibberellin A7 exhibits anti-Candida activity against Candia albicans .
    Gibberellin A7
  • HY-W714151

    Gg4cer; AsialoGAnglioside gm1; Asialo gm1, GAngliotetraosylceramide; Asialo GAnglioside gm1a [...]; GAnglio-n-tetraosylceramide; Asialo gm1 GAnglioside; AsialoGAnglioside gt1b

    Biochemical Assay Reagents Metabolic Disease
    Ganglioside ga1 (Gg4cer; Asialoganglioside gm1; Asialo gm1, Gangliotetraosylceramide; Asialo ganglioside gm1a [...]; Ganglio-n-tetraosylceramide; Asialo gm1 ganglioside; Asialoganglioside gt1b) is an ester product.
    Ganglioside ga1
  • HY-N11645

    GA-Mf

    Apoptosis Cancer
    Ganoderic acid Mf is an antitumor triterpenoid. Ganoderic acid Mf causes cell cycle arrest in the G1 phase. Ganoderic acid Mf shows high selectivity between normal and cancer cells and induces cell apoptosis via mitochondria mediated pathway .
    Ganoderic acid Mf
  • HY-102007

    HSP Cancer
    Gamitrinib TPP is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity.
    Gamitrinib TPP
  • HY-102007A

    HSP Cancer
    Gamitrinib TPP hexafluorophosphate is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP hexafluorophosphate is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity.
    Gamitrinib TPP hexafluorophosphate
  • HY-139351

    GA4+7

    Endogenous Metabolite Others
    Gibberellins A4/A7 induces stimulation of tracheid production in the terminal shoot of intact plants is mediated through an increase in the IAA level in the cambial region .
    Gibberellins A4/A7
  • HY-D2297

    Fluorescent Dye Others
    AIE-GA is a Golgi apparatus (GA) fluorescent probe (green channel: λex = 405 nm, λem = 500-700 nm). AIE-GA has a favourable binding ability to interact with COX-2. AIE-GA binds to the cyclooxygenase catalytic site of COX-2 .
    AIE-GA
  • HY-W614269

    Radionuclide-Drug Conjugates (RDCs) Others
    DOTA-GA(tBu)4 is a DOTA derivative similar to NOTA-GA. DOTA-GA(tBu)₄ is a tert-butyl-protected chelating agent used for the synthesis of DOTA-GA-TATE conjugates. The structure of DOTA-GA(tBu)4 allows for convenient conjugation to the N-terminus of peptides. DOTA-GA(tBu)4 can be used in research on medical imaging and diagnosis .
    DOTA-GA(tBu)4
  • HY-128873

    ADC Cytotoxin DNA Alkylator/Crosslinker Cancer
    Duocarmycin GA is an antibody agent conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin GA can be used against multi-agent resistant cell lines.
    Duocarmycin GA
  • HY-157977

    Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents MMP Cancer
    DOTA-GA-maleimide is a bifunctional chelator containing a DOTA macrocycle chelator, a GA linker, and a maleimide reactive group. DOTA-GA-maleimide can achieve radiolabeling of proteins by forming a stable coordination complex between the DOTA macrocycle and radioactive metal ions (such as 111In) through the specific binding of maleimide to protein thiol groups. DOTA-GA-maleimide can be used for SPECT imaging studies of MMP activity-related cancers .
    DOTA-GA-maleimide
  • HY-W187279

    Phytohormone Others
    Karrikin 2 is a seed germination stimulant. Karrikin 2 increases expression of the gibberellin (GA) biosynthesis genes GA3ox1 and GA3ox2 and the GA4-responsive gene CP1 in A. thaliana seeds .
    Karrikin 2
  • HY-136312

    HSP Cancer
    17-DMAP-GA, a Geldanamycin (HY-15230) analogue, is an inhibitor of HSP90. 17-DMAP-GA causes cell cycle abnormalities .
    17-DMAP-GA
  • HY-130997

    ADC Cytotoxin HSP Infection Cancer
    17-GMB-APA-GA is an ADC Cytotoxin. 17-GMB-APA-GA is a potent HSP90 inhibitor and used for latent T. gondii infection research .
    17-GMB-APA-GA
  • HY-N14924

    Bacterial Infection
    Oganomycin GA is Streptomyces str. oganonensis Y-G 19Z and Oganomycin A is produced when p-hydroxycinnamate sodium salt is added to the fermentation medium. Under the action of D-amino acid oxidase, A generates glutaryl derivative, GA; A and GA were converted to B and GB by acid hydrolysis to remove sulfate esters. The effect of B on d-amino acid oxidase was also changed to GB. A and B were more stable than A and B of cemycin, and had stronger effect against Gram-positive and Gram-negative bacteria than Gram-positive bacteria .
    Oganomycin GA
  • HY-150240

    Liposome Cancer
    DOPE-GA can be used in the preparation of liposomes for research on drug delivery and other applications .
    DOPE-GA
  • HY-171030

    Ferroptosis Cancer
    Pro-GA is a γ-Glutamylcyclotransferase (GGCT) inhibitor and a cell-permeable diester-type pro-drug with anticancer activity, GGCT is a key enzyme in glutathione metabolism and is involved in the ferroptosis pathway. Pro-GA exhibits an IC50 of 57 μM against the bladder cancer cell line T24 and can be utilized in cancer research .
    Pro-GA
  • HY-N3781

    Others Others
    Dregeoside Ga1 is a Steroids product that can be isolated from the herbs of Dregea volubilis .
    Dregeoside Ga1
  • HY-164569

    Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2 DOTA-GA is a DOTA-based metal chelator that can be used to prepare radionuclide drug conjugates (RDCs) whose carboxylic acid groups can complex metal ions. For example, NH2 DOTA-GA complexes Gd(III) ions.
    NH2 DOTA-GA
  • HY-159181

    Biochemical Assay Reagents Others
    p-NCS-Bz-DOTA-GA is a bifunctional chelator.
    p-NCS-Bz-DOTA-GA
  • HY-159180

    Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Others
    p-NCS-Bz-NODA-GA is a bifunctional chelator.
    p-NCS-Bz-NODA-GA
  • HY-133570

    HSP ADC Cytotoxin Cancer
    17-AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. ADCs Toxin .
    17-AEP-GA
  • HY-158089

    Biochemical Assay Reagents Others
    PLGA-COOH (MW 80000) (LA/GA 50:50) is a copolymer, which consist of lactic acid (LA)-glycolic acid (GA) with a molar ratio of 50:50, and a carboxyl terminal groups. PLGA-COOH (MW 80000) (LA/GA 50:50) is utilized in drug delivery system for its biocompatibility and biodegradability .
    PLGA-COOH (MW 80000) (LA/GA 50:50)
  • HY-164594

    Radionuclide-Drug Conjugates (RDCs) Cancer
    TA-DOTA-GA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    TA-DOTA-GA
  • HY-164577

    Radionuclide-Drug Conjugates (RDCs) Cancer
    BCN-DOTA-GA is a cyclooctyne-linked DOTA chelator that can be labeled with radioactive zirconium-89 and used as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells or tissues.
    BCN-DOTA-GA
  • HY-158255

    Biochemical Assay Reagents Others
    mPEG-PLGA (2000-80000) (LA/GA 50:50) is a copolymer, which consists of hydrophilic mPEG and biodegradable PLGA (molar ratio is 50:50) with a molecular weight of 2000 (mPEG) + 80000 (PLGA). mPEG-PLGA (2000-80000) (LA/GA 50:50) forms nanoparticles or microparticles, which is stable in aqueous solution at different pH values and elevated temperatures as well as in serum. mPEG-PLGA (2000-80000) (LA/GA 50:50) is utilized as carrier material in drug delivery systems .
    mPEG-PLGA (2000-80000) (LA/GA 50:50)
  • HY-156829

    Biochemical Assay Reagents Cancer
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) is a matrix materia, with lactic acid (LA):glycolic acid (GA) = 1:1, that acts as anti-cancer drug delivery. PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) can improve a drug's bioavailability, efficacy, water solubility, drug encapsulation efficiency, sustained drug release, and to minimize undesirable toxicity .
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1)
  • HY-156829A

    Biochemical Assay Reagents Cancer
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) is a matrix materia, with lactic acid (LA):glycolic acid (GA) = 15:1, that acts as anti-cancer drug delivery. PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) can improve a drug's bioavailability, efficacy, water solubility, drug encapsulation efficiency, sustained drug release, and to minimize undesirable toxicity .
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1)
  • HY-156829C

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1)
  • HY-156829I

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution)
  • HY-156829J

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution)
  • HY-148776

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) has a molecular weight of 20kDA to 5.0kDA and contains a 50:50 ratio of lactic acid (LA) to glycolic acid (GA) molecules. The molecular ratio of LA to GA determines the rate of matrix degradation and protein re-release .
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50)
  • HY-156829B

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors. The gelation temperature varies with concentration. The higher the concentration, the lower the gelation temperature. The gelation temperature is between 31-34℃ at a concentration of 15-20 wt% .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1)
  • HY-164588

    Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2-PEG4-NODA-GA is a NODA-type metal chelator that can bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NH2-PEG4-NODA-GA
  • HY-148775B

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60) has a molecular weight of 60kDA to 3.4kDA and contains a 75:25 ratio of lactic acid (LA) to glycolic acid (GA) molecules .
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60)
  • HY-148775

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) has a molecular weight of 60kDA to 3.4kDA and contains a 75:25 ratio of lactic acid (LA) to glycolic acid (GA) molecules .
    PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)
  • HY-156829E

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (15% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (15% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors. The gelation temperature varies with concentration. The higher the concentration, the lower the gelation temperature. The gelation temperature is between 31-34℃ at a concentration of 15-20 wt% .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (15% solution)
  • HY-156829H

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (20% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (20% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors. The gelation temperature varies with concentration. The higher the concentration, the lower the gelation temperature. The gelation temperature is between 31-34℃ at a concentration of 15-20 wt% .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (20% solution)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: